Persistent pulmonary subsolid nodules: How long should they be observed until clinically relevant growth occurs?

During the first two decades of 21^st century, there has been remarkable advance in the knowledge about lung cancer. One of the most important advances is persistent pulmonary subsolid nodules (SSNs) including pure ground-glass nodules (GGNs) and part-solid nodules (PSNs). Pulmonary SSNs, when persistent, have high probability of being pulmonary adenocarcinomas spectrum pathologically, and ironically show very indolent clinical courses over follow-ups (1-3). Many researchers investigated the natural history of persistent pulmonary SSNs, which included the frequency and pattern of interval growth, and the growth rate, to determine optimal management plan of patients with these nodules (4-8). However, uncertainty still remains on the natural course of persistent SSNs, especially with respect to the long-term consequences and ideal timing for surgical resection.

Recently, Tang et al. reported a noteworthy article regarding the natural history of SSNs (9). In this single-center, retrospective study, the authors included 128 persistent SSNs (93 pure GGNs and 35 PSNs) 3 cm or smaller from 128 participants, and reported their observation during long term follow-ups (average of 3.6 years, maximum follow-up period of 12 years). This study was novel in that the authors subdivided the growth of SSNs into three categories: (I) true SSN growth, defined as increase of whole lesion diameter or solid component diameter of ≥2 mm, or new solid component of ≤2 mm within the previous pure GGN, from the baseline CT scan; (II) substantial SSN growth, defined as increase of whole lesion diameter or solid component diameter of ≥5 mm, from the baseline CT scan; and (III) stage shift, defined as detection of the specific shift to different T-categories or TNM stages according to the seventh edition of TNM staging system on follow up CT scan (10), compared with the initial CT scan. Determination of the growth of SSNs is not a simple task because there is considerable intra- and inter-observer variability in measurement of SSNs, not only for the size of whole lesion, but also for the size of solid component (11-13). Most of previous studies investigating natural history of SSNs defined the threshold of growth as 2 mm increase in size, either for whole lesion diameter or solid component diameter (4-8,13,14). By extending the threshold of growth to 5 mm and shift in T-categories/cancer stages, Tang et al. provided new and interesting insight in natural history of SSNs, because minimal growth of 2 mm of SSN may not necessarily indicate progression to invasive disease or necessity of surgical intervention, especially for pure GGNs.

In this study, pure GGNs exhibited median progression times of 7, 9, and 12 years for true growth, substantial growth, and stage shift, respectively, which may justify longer follow-up intervals for pure GGNs than those suggested by guidelines (15,16). Fleischner Society guideline for management of incidental pulmonary nodules recommends biennial CT follow-up for pure GGNs (15). However, the interval can be further delayed without concern of substantial growth or stage shift, considering the results of this study. Actually, in a recent study, simulation analyses with follow-up CT intervals of 1-, 2-, and 3-year for pure GGNs showed similar outcome in terms of survival (17). For PSNs, the study reported median progression times of 3, 3, and 9 years for true growth, substantial growth, and stage shift, respectively, which is much shorter than those of pure GGNs, but still indicating indolent behavior. Several previous studies reported more indolent behavior of PSNs with small solid component (i.e., solid part size of 5 mm or smaller) (8,18), and they suggested more conservative management strategy with biennial follow-up after first annual follow-up CT can be applied in those PSNs with small solid components in this context (8,19).

Another important information in this kind of research is risk factors or predictors of growing SSNs. Although it is now generally accepted that adenocarcinomas manifested as SSNs have indolent natural course (14,19,20), the clinical behavior of individual SSN can be diverse. In this study, for example, the time interval to substantial growth varied from 3 to 12 years for pure GGNs, and from 1 year to 7 years for PSNs. Therefore, identification of SSNs with high risk for growth and progression to higher stages is critical in the clinical decision making of these nodules. Risk factors for SSNs’ growth have been reported to include old age, male, larger whole lesion size or larger solid component size, presence of solid component, and history of previous lung cancer (5,6,8,21,22). The current study also demonstrated PSNs showed interval growth more frequently and their time to progression was much shorter.

The authors claimed that reaching threshold of substantial growth can be the optimal timing for surgical resection. This is an interesting suggestion, however we have a somewhat different opinion on this issue. Actually, we believe the size of solid component is more critical determinant for surgical resection rather than the occurrence of growth. The solid component within PSNs reflects the pathological invasive component of adenocarcinoma (23), and is one of the most important prognostic indicators in lung cancers manifested as PSNs (11), which was incorporated in the recent version of TNM staging system (24). The current management guidelines also indicate PSNs with solid component of 6mm or greater as highly suspicious lesions (15,16).

Possibility of underlying selection bias should be considered when interpreting this kind of retrospective study. In this study, 5-year growth rate in terms of true growth (35.5% for pure GGNs and 67.3% for PSNs) was much higher compared with a previous multicenter prospective study [14% for pure GGNs and 48% for PSNs (only including lesions with visible solid component on mediastinal window)] (6). SSNs included in this study may have been more aggressive in nature, compared with previous studies. Furthermore, surgical excision rate (48.4%, 62/128) was quite high, exceeding the number of cases exhibited true SSN growth. Due to the resected cases of SSNs before growth, there can be possibility of underestimation of their time to growth and overestimation of the growth rate of included SSNs.

Another important pitfall in interpreting the time to growth in a retrospective study is that CT follow-up intervals are not standardized or uniform. Sometimes, it may be impossible to know the exact time point of growth. In this context, calculation of the growth rate based on follow-up CTs can be an alternative method to evaluate the growth of SSNs (18).

Lastly, it should be mentioned that the stage shifts of SSNs in this study was defined according to the 7^th edition of TNM staging system, which measures entire nodule size of SSNs, rather than solid component (10). Therefore, the results regarding the time to stage shift cannot be directly applied in the current standard of management.

In spite of various researches to answer the questions about the natural history of SSNs, generalization of their results is still limited because they were mostly retrospective, single-center studies, which could be biased by different population, imaging and follow-up protocols, and definition of outcomes. Although there was a prospective, multi-center study, the population size was relatively small, especially for PSNs and surgically resected lesions, and management protocol was not fully standardized (6). To further investigate the natural history SSNs and to predict SSNs at risk of progression, large-scaled, multi-center prospective cohort study is definitely warranted.

In conclusion, to support the ideal clinical decision making in management of patients with SSNs, a thorough understanding of their natural history is essential, however several important questions remained unanswered.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009;253:606-22. [Crossref] [PubMed]
2. Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol 2002;178:1053-7. [Crossref] [PubMed]
3. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85. [Crossref] [PubMed]
4. Chang B, Hwang JH, Choi YH, et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. Chest 2013;143:172-8. [Crossref] [PubMed]
5. Cho J, Kim ES, Kim SJ, et al. Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent Growth. J Thorac Oncol 2016;11:1453-9. [Crossref] [PubMed]
6. Kakinuma R, Noguchi M, Ashizawa K, et al. Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study. J Thorac Oncol 2016;11:1012-28. [Crossref] [PubMed]
7. Kobayashi Y, Fukui T, Ito S, et al. How long should small lung lesions of ground-glass opacity be followed? J Thorac Oncol 2013;8:309-14. [Crossref] [PubMed]
8. Lee JH, Park CM, Lee SM, et al. Persistent pulmonary subsolid nodules with solid portions of 5 mm or smaller: Their natural course and predictors of interval growth. Eur Radiol 2016;26:1529-37. [Crossref] [PubMed]
9. Tang EK, Chen CS, Wu CC, et al. Natural History of Persistent Pulmonary Subsolid Nodules: Long-Term Observation of Different Interval Growth. Heart Lung Circ 2018. [Epub ahead of print]. [Crossref] [PubMed]
10. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. [Crossref] [PubMed]
11. Hwang EJ, Park CM, Ryu Y, et al. Pulmonary adenocarcinomas appearing as part-solid ground-glass nodules: is measuring solid component size a better prognostic indicator? Eur Radiol 2015;25:558-67. [Crossref] [PubMed]
12. Kim H, Park CM, Song YS, et al. Measurement Variability of Persistent Pulmonary Subsolid Nodules on Same-Day Repeat CT: What Is the Threshold to Determine True Nodule Growth during Follow-Up? PLoS One 2016;11:e0148853. [Crossref] [PubMed]
13. Kakinuma R, Ashizawa K, Kuriyama K, et al. Measurement of focal ground-glass opacity diameters on CT images: interobserver agreement in regard to identifying increases in the size of ground-glass opacities. Acad Radiol 2012;19:389-94. [Crossref] [PubMed]
14. Kakinuma R, Muramatsu Y, Kusumoto M, et al. Solitary Pure Ground-Glass Nodules 5 mm or Smaller: Frequency of Growth. Radiology 2015;276:873-82. [Crossref] [PubMed]
15. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017;284:228-43. [Crossref] [PubMed]
16. American College of Radiology. Lung CT screening reporting and data system (Lung-RADS). Reston, VA: American College of Radiology 2014.
17. Hammer MM, Palazzo LL, Eckel AL, et al. A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. Radiology 2019;290:506-13. [Crossref] [PubMed]
18. Song YS, Park CM, Park SJ, et al. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy. Radiology 2014;273:276-84. [Crossref] [PubMed]
19. Lee JH, Park CM, Kim H, et al. Persistent part-solid nodules with solid part of 5 mm or smaller: Can the 'follow-up and surgical resection after interval growth' policy have a negative effect on patient prognosis? Eur Radiol 2017;27:195-202. [Crossref] [PubMed]
20. Yankelevitz DF, Yip R, Smith JP, et al. CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds. Radiology 2015;277:555-64. [Crossref] [PubMed]
21. Hiramatsu M, Inagaki T, Inagaki T, et al. Pulmonary ground-glass opacity (GGO) lesions-large size and a history of lung cancer are risk factors for growth. J Thorac Oncol 2008;3:1245-50. [Crossref] [PubMed]
22. Lee SW, Leem CS, Kim TJ, et al. The long-term course of ground-glass opacities detected on thin-section computed tomography. Respir Med 2013;107:904-10. [Crossref] [PubMed]
23. Lee KH, Goo JM, Park SJ, et al. Correlation between the size of the solid component on thin-section CT and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules. J Thorac Oncol 2014;9:74-82. [Crossref] [PubMed]
24. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51. [Crossref] [PubMed]